跳转至内容
Merck

T1975000

三唑仑

European Pharmacopoeia (EP) Reference Standard

别名:

8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H12Cl2N4
CAS号:
分子量:
343.21
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

triazolam

製造商/商標名

EDQM

藥物控制

USDEA Schedule I
regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

ClC1=CC=CC=C1C2=NCC3=NN=C(C)N3C4=CC=C(Cl)C=C42

InChI

1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3

InChI 密鑰

JOFWLTCLBGQGBO-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Triazolam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazard

訊號詞

Warning

危險聲明

危險分類

Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Helen E Cubitt et al.
Xenobiotica; the fate of foreign compounds in biological systems, 41(8), 623-638 (2011-03-26)
Prediction of metabolic clearance in extreme individuals rather than the 'average human' is becoming an attractive tool within the pharmaceutical industry. The current study involved prediction of variability in metabolic clearance for alprazolam, triazolam and midazolam with emphasis on the
A J Rothschild
The Journal of clinical psychiatry, 53 Suppl, 69-79 (1992-12-01)
In the past 18 months, there has been considerable controversy regarding the benzodiazepine triazolam (Halcion). To review data supporting or not supporting the assertion that treatment with triazolam results in adverse reactions more frequently than with other benzodiazepines, the author
P D Kroboth et al.
Drug intelligence & clinical pharmacy, 17(7-8), 495-500 (1983-07-01)
Triazolam is a sedative/hypnotic triazolobenzodiazepine, structurally related to alprazolam. Recently, it has been approved for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Triazolam is metabolized with a half-life of
B L Lobo et al.
The Annals of pharmacotherapy, 31(5), 625-632 (1997-05-01)
To review the literature that compares zolpidem with triazolam, with an emphasis on efficacy and safety in humans. Information was retrieved from a MEDLINE search (1983-1996) of the English-language literature using the terms triazolam and zolpidem. Reports of clinical trials
David J Greenblatt et al.
The Journal of pharmacy and pharmacology, 63(2), 214-221 (2011-01-18)
Ketoconazole is extensively used as an index inhibitor of cytochrome P450-3A (CYP3A) activity in vitro and in vivo, but the mechanism of ketoconazole inhibition of CYP3A still is not clearly established. Inhibition of metabolite formation by ketoconazole (seven concentrations from

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门